Assessing quality of life in patients with cutaneous lymphoma
Official title: Assessment of Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
Run by City of Hope Medical Center · NCT04670874 · Data updated 2026-11-12
This study looks at how living with cutaneous lymphoma affects adults' quality of life and what support they might need to feel better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1250 (estimated) |
| Sponsor | City of Hope Medical Center Academic / other |
| Locations | 1 site (Duarte, California) |
| Status | Recruiting |
| Started | August 17, 2023 |
| Main results expected | January 24, 2034 |
| Study ends | January 24, 2034 |
| Registry record updated | January 28, 2026 |
| Trial ID | NCT04670874 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults with a presumed or confirmed diagnosis of cutaneous lymphoma.
✕Probably not a fit
Patients without a diagnosis of cutaneous lymphoma or those who do not agree to participate in the research may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the quality of life in adult patients diagnosed with cutaneous lymphoma using the Skindex-29 questionnaire. It aims to identify the psychosocial needs of patients, assess the burden of pruritus, and correlate quality of life with demographic and clinical factors. Additionally, the study tracks patients' understanding of their diagnosis and their need for resources related to their care. By gathering this information, the study seeks to improve the overall quality of life for individuals affected by this rare type of cancer.
Why it matters
Potential benefit: If successful, this study could lead to improved support and resources for patients with cutaneous lymphoma, enhancing their quality of life.
How similar studies have gone: While there have been studies assessing quality of life in cancer patients, this specific focus on cutaneous lymphoma and the use of the Skindex-29 questionnaire is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Agreement to participate in the research study * Presumed or confirmed diagnosis of CL
Where it's running
-
City of Hope Medical Center
Duarte, California, United States Recruiting
Study contacts
- Principal investigator: Christiane Querfeld — City of Hope Medical Center
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma
This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.
-
Ropeginterferon treatment for cutaneous T‑cell lymphoma
This trial tests whether ropeginterferon-alfa-2b helps people with cutaneous T‑cell lymphoma who have not responded adequately to multiple prior skin-directed therapies.
-
Personalized exercise and nutrition program to reduce cancer-related fatigue
This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).
-
Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas
This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.
-
Tofacitinib cream for treating early-stage Cutaneous T-cell Lymphoma
This study is testing if a new cream can help people with early-stage Cutaneous T-cell Lymphoma feel better and improve their skin after 12 weeks of treatment.
-
Systemic treatments for cutaneous T‑cell lymphoma
This project looks at how different systemic treatments are used in adults with cutaneous T‑cell lymphoma to see which approaches are linked to longer disease control in routine care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.